Ahead of today’s R&D Day event, expected to start at 8:00 am ET, Moderna (NASDAQ:MRNA) says it plans to enter the seasonal flu business for influenza types A&B.
On the COVID-19 front, its large-scale Phase 3 clinical trial evaluating mRNA-1273 has now enrolled 25,296 participants.
https://seekingalpha.com/news/3614896-moderna-to-enter-seasonal-flu-vaccine-business
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.